Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company discovers, develops and commercializes therapeutics for managing and alleviating pain. The Company's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The Company is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The Company's other products are under development for the treatment of headache and neuropathic and rheumatological pain.